S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
S&P 500   5,254.35
DOW   39,807.37
QQQ   444.01
Stock market today: Asian shares are mostly higher after another set of Wall St records
Delta Airline’s Put Option Activity Isn’t Bad News
3 Value Stocks Too Small For Buffett’s Portfolio
Disney Stock Catches 3 Upgrades In a Single Week
7 Stocks That Will Drive the Weight Loss Drugs Market
Walgreens Boots Alliance: Deep Value With Nowhere to Go But Up
Krispy Kreme's Sweet Deal: McDonald's Partnership Sparks Growth?
NASDAQ:INKT

MiNK Therapeutics (INKT) Stock Price, News & Analysis

$0.91
0.00 (0.00%)
(As of 03/28/2024 ET)
Today's Range
$0.90
$0.93
50-Day Range
$0.84
$1.00
52-Week Range
$0.75
$3.34
Volume
35,063 shs
Average Volume
52,975 shs
Market Capitalization
$31.52 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$9.00

MiNK Therapeutics MarketRank™ Stock Analysis

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
890.9% Upside
$9.00 Price Target
Short Interest
Healthy
0.47% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.73mentions of MiNK Therapeutics in the last 14 days
Based on 14 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.59) to ($0.58) Per Share

Overall MarketRank

New Rank-Based ScoringMarketRank is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.

2.10 out of 5 stars

Medical Sector

598th out of 938 stocks

Biotechnology Industry

21st out of 38 stocks

INKT stock logo

About MiNK Therapeutics Stock (NASDAQ:INKT)

MiNK Therapeutics, Inc., a clinical stage biopharmaceutical company, engages in the discovery, development, and commercialization of allogeneic, off-the-shelf, invariant natural killer T (iNKT) cell therapies to treat cancer and other immune-mediated diseases. It's product candidate is AGENT-797, an off-the-shelf, allogeneic for iNKT cell therapy and treatment of various myeloma diseases and solid tumours, which is in Phase 1 clinical trials. The company was formerly known as AgenTus Therapeutics, Inc. MiNK Therapeutics, Inc. was incorporated in 2017 and is based in New York, New York. MiNK Therapeutics, Inc. operates as a subsidiary of Agenus Inc.

INKT Stock Price History

INKT Stock News Headlines

Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
MiNK Therapeutics (NASDAQ:INKT) PT Lowered to $9.00
Top Project Outperforms BTC in 2023…
According to a recently published report… One DeFi protocol boasted gains over 100% during one of the biggest crashes the crypto market has ever seen. And now, this crypto coin is set to soar in the parabolic bull run projected in 2024.
MiNK Reports Fourth Quarter and Year-End 2023 Results
Earnings Outlook For MiNK Therapeutics
MiNK Therapeutics Inc INKT
MiNK Therapeutics GAAP EPS of -$0.15
MiNK Therapeutics Reports Third Quarter 2023 Results
MiNK Therapeutics Insider Ups Holding During Year
See More Headlines
Receive INKT Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for MiNK Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

Company Calendar

Last Earnings
8/10/2023
Today
3/28/2024
Next Earnings (Estimated)
5/09/2024
Fiscal Year End
12/31/2024

Industry, Sector and Symbol

Sector
Medical
Industry
Biotechnology
Sub-Industry
N/A
Current Symbol
NASDAQ:INKT
Fax
N/A
Employees
31
Year Founded
N/A

Price Target and Rating

Average Stock Price Target
$9.00
High Stock Price Target
$9.00
Low Stock Price Target
$9.00
Potential Upside/Downside
+890.9%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
2 Analysts

Profitability

Net Income
$-22,460,000.00
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Book Value
($0.52) per share

Miscellaneous

Free Float
28,519,000
Market Cap
$31.52 million
Optionable
No Data
Beta
0.12
13 Stocks Institutional Investors Won't Stop Buying Cover

Which stocks are major institutional investors including hedge funds and endowments buying in today's market? Click the link below and we'll send you MarketBeat's list of thirteen stocks that institutional investors are buying up as quickly as they can.

Get This Free Report

Key Executives

  • Dr. Garo H. Armen Ph.D. (Age 71)
    Executive Chairman
  • Dr. Jennifer S. Buell Ph.D. (Age 49)
    President, CEO & Director
    Comp: $812.78k
  • Dr. Marcus Antonius van Dijk Ph.D. (Age 62)
    Chief Scientific Officer
    Comp: $369.92k
  • Ms. Christine M. Klaskin (Age 58)
    Treasurer
    Comp: $27.24k
  • Ms. Heather Boussios
    General Counsel & Chief Compliance Officer
  • Joy Zhou Ph.D.
    Vice President & Head of CMC

INKT Stock Analysis - Frequently Asked Questions

Should I buy or sell MiNK Therapeutics stock right now?

2 Wall Street equities research analysts have issued "buy," "hold," and "sell" ratings for MiNK Therapeutics in the last year. There are currently 2 buy ratings for the stock. The consensus among Wall Street equities research analysts is that investors should "buy" INKT shares.
View INKT analyst ratings
or view top-rated stocks.

What is MiNK Therapeutics' stock price target for 2024?

2 Wall Street research analysts have issued 1-year price targets for MiNK Therapeutics' stock. Their INKT share price targets range from $9.00 to $9.00. On average, they anticipate the company's share price to reach $9.00 in the next twelve months. This suggests a possible upside of 890.9% from the stock's current price.
View analysts price targets for INKT
or view top-rated stocks among Wall Street analysts.

How have INKT shares performed in 2024?

MiNK Therapeutics' stock was trading at $1.07 at the beginning of 2024. Since then, INKT stock has decreased by 15.1% and is now trading at $0.9083.
View the best growth stocks for 2024 here
.

Are investors shorting MiNK Therapeutics?

MiNK Therapeutics saw a increase in short interest during the month of March. As of March 15th, there was short interest totaling 46,500 shares, an increase of 12.6% from the February 29th total of 41,300 shares. Based on an average daily trading volume, of 54,800 shares, the short-interest ratio is currently 0.8 days. Currently, 0.5% of the company's stock are short sold.
View MiNK Therapeutics' Short Interest
.

When is MiNK Therapeutics' next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Thursday, May 9th 2024.
View our INKT earnings forecast
.

How were MiNK Therapeutics' earnings last quarter?

MiNK Therapeutics, Inc. (NASDAQ:INKT) released its earnings results on Thursday, August, 10th. The company reported ($0.18) EPS for the quarter, beating analysts' consensus estimates of ($0.19) by $0.01. During the same period last year, the company posted ($0.18) EPS.

When did MiNK Therapeutics IPO?

MiNK Therapeutics (INKT) raised $43 million in an initial public offering on Friday, October 15th 2021. The company issued 3,333,334 shares at $12.00-$14.00 per share.

Who are MiNK Therapeutics' major shareholders?

MiNK Therapeutics' stock is owned by a variety of institutional and retail investors. Top institutional investors include Citadel Advisors LLC (0.12%). Insiders that own company stock include Agenus Inc, Garo H Armen and Ulf Wiinberg.
View institutional ownership trends
.

How do I buy shares of MiNK Therapeutics?

Shares of INKT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.
Compare Top Brokerages Here.

This page (NASDAQ:INKT) was last updated on 3/29/2024 by MarketBeat.com Staff

From Our Partners